Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

33 patients with metastatic renal cell carcinoma were treated intradermally with an autologous (29 patients) or allogeneic (4 patients) irradiated tumor cell preparation mixed with Corynebacterium parvum given monthly after palliative nephrectomy (27 patients) or excision of tumor metastases (2 patients). No significant toxicity was produced. 8 patients (24%) underwent objective responses. Responding patients had a median survival of 32 months, the median survival of all patients was 17 months (differences not significant).
 ...
PMID:Autologous anticancer antigen preparation for specific immunotherapy in advanced renal cell carcinoma. 358 39

Recurrent or metastatic renal cell carcinoma (RCC) seldom and only briefly responds to hormonal therapy or chemotherapy, with little, if any, impact on overall survival; hence the prognosis is poor. Effects of both partially purified and recombinant interferons have been studied and have yielded response rates of 5% to 27%. In a review of 12 series, the complete and partial response rate was 16% (100 of 632 patients) with a 95% confidence interval of 13% to 19%. Response rates were similar for both partially purified and recombinant interferons. Although no dose-response effect has been clearly demonstrated, daily doses (5 to 10 megaunits) of interferon seem to be associated with the highest therapeutic index. Patient characteristics that suggest potential responsiveness to interferon include minimal or no prior therapy, good performance status, and pulmonary metastases. Although some investigators believe that patients with nephrectomy are more likely to be responsive, a careful review of published literature does not support this. Laboratory observations demonstrating synergistic activity of interferons combined with a variety of chemotherapeutic agents have led to clinical trials for exploring the potential of such treatment. Initial results of combining interferon and vinblastine are encouraging; further studies are under way. Substantial evidence now indicates that interferon is an effective agent in metastatic RCC.
 ...
PMID:Interferon therapy for renal cell carcinoma. 358 3

An 87-year-old man with extensive solar damage presented with a 2-month history of a dome-shaped, crusted lesion on the dorsum of the left hand. Microscopically, the tumor consisted of fascicles of spindle cells with bizarre nuclei and clear, vacuolated cytoplasm. Histochemical, immunohistochemical, and ultrastructural features supported the diagnosis of atypical fibroxanthoma. There was no evidence of metastatic disease. The lesion was completely excised, and there has been no recurrence in 3 months of observation. This unusual "clear cell" variant of atypical fibroxanthoma must be distinguished from other clear cell tumors, such as metastatic renal cell carcinoma, clear cell eccrine carcinoma, and clear cell sarcoma (malignant melanoma) of soft parts. Although atypical fibroxanthoma is usually cured by complete surgical excision, metastases have been reported.
 ...
PMID:"Clear cell" atypical fibroxanthoma. 365 81

Nine cases of metastatic renal cell carcinoma to the lung were studied to assess the efficacy of surgical management. Between January, 1965 and December 1981, 116 cases of metastatic renal cell carcinoma to the lung were treated. Nine of these cases (7.8%), were treated with surgical resection for the pulmonary metastases. The overall crude survival rate after pulmonary resection was 33.3% (3/9) at 3 years and 22.2% (2/9) at 5 years. Two patients are long-term survivors, one still being in good health 108 months, and the other 72 months after pulmonary resection. Pulmonary resection for metastatic renal cell carcinoma was considered effective in some selected slow-growing cases as protection against metastasis from a metastasis.
 ...
PMID:[Results of pulmonary resection for metastatic renal cell carcinoma]. 368 39

Arterial embolization was performed for the relief of pain in 4 patients with symptomatic osseous metastases associated with extensive soft tissue tumors. Two patients had metastatic transitional cell carcinoma of the bladder and renal pelvis, and 2 had metastatic renal cell carcinoma. Three of the 4 patients experienced significant relief of pain and improved performance status. Decrease of tumor size or healing of osteolytic metastasis did not occur. Errant embolization occurred in one patient but did not become a serious problem. In 3 patients post-infarction pain occurred, but subsided within 36 hours. This therapeutic approach may be useful to control the pain associated with a massive advanced uroepithelial cancer.
 ...
PMID:[Transcatheter embolization in the management of pain from metastatic uroepithelial cancer]. 375 95

The deoxyribonucleic acid content of tumor specimens from 23 patients with metastatic renal cell carcinoma was analyzed prospectively by flow cytometry and static cytophotometry. Of the primary tumors 10 (43 per cent) were homogeneously diploid or near diploid in 8 samples studied from each tumor and 13 (57 per cent) had an aneuploid deoxyribonucleic acid content in 1 to 8 samples. At the end of followup 9 of 10 patients with diploid or near diploid primary tumors were alive, compared to only 1 of 13 with aneuploid primary tumors. Patients with homogeneously diploid or near diploid tumors survived significantly longer compared to those with aneuploid tumor deoxyribonucleic acid content (p less than 0.001). After excision of solitary diploid or near diploid metastases 4 patients had no evidence of disease. In 3 of these patients the primary tumors were diploid or near diploid, whereas 1 had 1 aneuploid and 7 diploid or near diploid samples in the primary tumor. In 10 other patients 28 metastases revealed concordance in deoxyribonucleic acid content with the primary tumors. Our results indicate that deoxyribonucleic acid content might be a useful prognostic discriminator with implications for the clinical management of patients with metastatic renal cell carcinoma.
 ...
PMID:Prognostic value of deoxyribonucleic acid content in metastatic renal cell carcinoma. 376 35

Radical nephrectomy and excision of metastases were performed in 21 patients with metastatic renal cell carcinoma. Followup was 12 years. Eight patients had metastases at the time of diagnosis and survived an average of 54 months, with 50 per cent alive 5 years postoperatively. Metastases developed after nephrectomy for localized disease in 13 patients. After extirpation of the secondary lesions these 13 patients survived an average of 38 months and 25 per cent were alive at 5 years. Survival varied with the length of time free of disease. Patients in whom metastases developed later than 2 years after nephrectomy survived 55 months compared to only 22 months for those in whom metastases developed earlier. Survival also was influenced by tumor aggressiveness (reflected by prognostic index number) and completeness of surgical excision of the secondary lesion.
 ...
PMID:Aggressive treatment of metastatic renal cancer. 376 36

Polyinosinic-polycytidylic acid, a double-stranded ribonucleic acid that is a potent inducer of interferon production, was used in a stabilized form to treat 11 patients with metastatic renal cell carcinoma. Seven patients completed a full course of 8 infusions at maximum tolerated dosage. All patients experienced transient fever and marked fatigue. Anorexia was mild. Transient leukopenia occurred in 3 patients and reversible elevation in creatinine was observed in 1. All 4 patients with brain metastases became lethargic, and 3 died during or shortly after therapy. Only 2 patients demonstrated measurable total regression of isolated metastases (pleural/pulmonary in 1 and bone in 1) but in both metastases at other sites progressed. No partial regressions were seen. Metastases at all other sites (liver, brain and renal fossa) progressed during therapy. Patients who appeared to respond and who performed best during therapy generally demonstrated a higher performance status initially. Expression of natural cytotoxicity in in vitro testing did not correlate with a demonstrated response to treatment.
 ...
PMID:Immunotherapy of metastatic renal cell carcinoma with polyinosinic-polycytidylic acid. 380 4

Twenty patients with measurable metastatic renal cell carcinoma (RCC) were were treated with interferon alfa-2a (Roferon-A), 36 X 10(6)U intramuscularly 3 times weekly, alone (2 patients) or in combination with vinblastine, 0.10-0.15 mg/kg intravenously every 2 to 3 weeks. Objective responses in the lung, bone, liver, and lymph node metastases were seen in 6 of 18 evaluable patients. Dose reduction of interferon alfa-2a was necessary in 19 of the 20 patients due to intolerable flu-like side effects and fatigue. Bone marrow suppression and increase of gamma-GT represented the most often observed objective toxicity. The preliminary results of this combination treatment in RCC are promising and warrant randomized studies exploring the role of vinblastine. The dose of interferon alfa-2a should be reduced by 50% to avoid excessive toxicity and to maximize patient compliance.
 ...
PMID:Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma. 394 41

The literature provides few examples of regression of documented metastatic renal cell carcinoma. We report a case of cytologically documented pulmonary metastases from a renal cell carcinoma, which resolved following nephrectomy and hormonal therapy. The patient has been followed for 6 years without evidence of recurrence.
 ...
PMID:Regression of metastatic renal cell carcinoma: a case report and literature review. 395 24


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>